Nevertheless, data from the survival prognosis analysis of the MXD3 gene suggested distinct conclusions for different tumors, as we observed that MXD3 predicted worse survival of PRAD, MESO, LGG, KICH, UVM, LUAD, KIRC, ACC, THYM, HNSC, LICH, and GBM cohorts. This evidence concerns the gene MXD3 and glioblastoma.